Established immune markers still maintain their relevance for clinical decision-creating in breast cancer treatment with even extended meanings. Estrogen receptor (ER) amount shouldn't only be classified in constructive or unfavorable. Small ER stages ≤ten% of labeled cells must be taken care of in another way (LoE 1a/A/Back++). Tumors with https://jesset865xir5.blog2news.com/profile